Dawnrays Pharmaceutical (Holdings) Limited has been informed by AD Pharmaceuticals that approval obtained to initiate a controlled Phase III clinical trial of randomized, double-blind, placebo to evaluate the long-term efficacy and safety of Ebronucimab (AK102) in patients with primary hypercholesterolemia and mixed hyperlipidemia.